Eric Vermaas

Title: Eric Vermaas: Innovator in Biomolecular Aptamers

Introduction

Eric Vermaas is a notable inventor based in Oakland, California. He has made significant contributions to the field of biomolecular research, particularly through his innovative work on aptamers. His expertise and dedication have led to advancements that hold promise for therapeutic and diagnostic applications.

Latest Patents

Vermaas holds a patent for "Aptamers specific for biomolecules and methods of making." This patent describes a method for identifying oligomer sequences that specifically bind to target molecules such as serum proteins, kinins, eicosanoids, and extracellular proteins. The technique involves complexation of the target molecule with a mixture of oligonucleotides, which includes random sequences and sequences that serve as primers for PCR. This method allows for the generation of aptamers that bind to various important molecules, including serum Factor X, PDGF, FGF, ICAM, VCAM, E-selectin, thrombin, bradykinin, and PGF2. The process includes several steps, such as complexation, separation, amplification, and recovery of the oligonucleotides, which can then be sequenced for further applications.

Career Highlights

Eric Vermaas is currently employed at Gilead Sciences, Inc., where he continues to push the boundaries of biomolecular research. His work has not only contributed to the scientific community but has also paved the way for potential therapeutic solutions.

Collaborations

Throughout his career, Vermaas has collaborated with esteemed colleagues, including Linda C. Griffin and Glenn Albrecht. These collaborations have enriched his research and expanded the impact of his innovations.

Conclusion

Eric Vermaas is a distinguished inventor whose work on aptamers has the potential to revolutionize therapeutic and diagnostic methods. His contributions to biomolecular research are invaluable and continue to inspire advancements in the field.